US FDA On Resuming Normal Manufacturing Operations When Pandemic Recedes
Executive Summary
Focus on restarting production, easing drug shortages and completing quality assurance activities for quarantined batches, agency guidance says.
You may also be interested in...
The Steps Drug Makers Must Take Now To Avoid A Post-COVID-19 Manufacturing Crisis
How pharmaceutical companies should plan to catch up after the pandemic and explain what happened to inspectors.
US FDA issues new guideline on emergency plans
The US Food and Drug Administration has issued final guidance aimed at encouraging manufacturers of so-called "medically necessary drug products" and their raw materials and components to develop contingency production plans for use during emergencies that result in high absenteeism at production facilities.
US FDA Assesses Over 500 Biopharma Plants Remotely Via Records Review; Refines Process
Agency may share outcomes of remote record reviews in lieu of inspections at US and foreign facilities.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available Buy Reports
Need a specific report? 1000+ reports available Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: